Try a new search

Format these results:

Searched for:

person:rekawp01

in-biosketch:true

Total Results:

22


Accuracy of third trimester ultrasound in predicting neonatal birthweight in patients with inflammatory bowel disease

Roy-McMahon, Christine; Rekawek, Patricia; Anne Bigelow, Catherine; Raymond, Samantha; Overbey, Jessica R.; Dubinsky, Marla C.; Teresa Mella, Maria
Objective: To evaluate the accuracy of third trimester ultrasound in predicting birthweight in patients with inflammatory bowel disease (IBD) using the gestation-adjusted projection (GAP) method. Study design: Retrospective cohort study including pregnant patients with IBD who had third trimester ultrasounds and delivered at a single institution from 2012 to 2017. Controls included pregnant patients without IBD seen during the study period with third trimester ultrasounds. Correlation plots of GAP birthweight and actual birthweight (AB) were created for IBD-positive cases, IBD-negative controls, and IBD-positive cases with and without prior abdominal surgery. GAP predicted birthweight error was calculated for cases and controls. Univariable linear regression models estimated the association between predicted birthweight and AB. Multivariable linear regression models estimated the association between GAP birthweight and AB adjusting for age, BMI, race, and IBD status. Results: 320 patients were included (172 cases and 148 controls). Cases were more likely to be older (p < 0.001), white (p < 0.001), and have a lower BMI (p = 0.001). Correlation plots of GAP birthweight and AB showed linear correlations in cases (Spearman ρ = 0.81), controls (ρ = 0.74), cases with (p = 0.78) and without prior surgery (ρ = 0.83). GAP birthweight was significantly associated with AB in controls and cases in univariable linear regression models (β = 0.85, standard error = 0.04, p < 0.001; β = 0.90, standard error = 0.06, p < 0.001, respectively). No significant difference was found between the parameter estimates of the two models (p = 0.47). GAP birthweight remained significantly associated with AB in a multivariable linear regression model (β = 0.86, standard error = 0.03, p < 0.001). There were no significant differences between GAP predicted birthweight error between controls and cases (APE 11% vs 10% respectively, p = 0.56) and between cases without and with prior surgery (APE 10% vs 11%, p = 0.7). Conclusion: The accuracy of fetal biometry in the third trimester for predicting actual birthweight was equivalent between patients with and without IBD and those with prior abdominal surgery.
SCOPUS:85112399061
ISSN: 0301-2115
CID: 5002262

Peripartum Exposure to Biologic Therapy Does Not Impact Postpartum Wound Healing in Women With IBD

Aboubakr, Aiya; Gottlieb, Zoë S; Riggs, Alexa Rae; Johnson, Shaelyn O'Hara; Jimenez, Darwin; Rekawek, Patricia; Mella, Maria Teresa; Dubinsky, Marla C
BACKGROUND:Inflammatory bowel disease (IBD) commonly affects women during childbearing years and often requires antepartum therapy. Data regarding effects of biologic exposure on delivery outcomes are limited. We explored whether peripartum biologic exposure impacts wound healing following cesarean section (C-section) and vaginal delivery (VD) in IBD patients. METHODS:Pregnancy and IBD data from the IBD Preconception and Pregnancy Planning (I-PrePP) Clinic database were collected and analyzed. Primary outcome was frequency of postpartum wound infection in women receiving peripartum biologics, defined as exposure in the third trimester and up to 2 weeks postdelivery relative to nonexposed patients. Secondary outcomes included effect of peripartum biologic timing and IBD phenotype on wound healing. Descriptive statistics summarized data using frequency for categorical variables and median for continuous variables. Univariate analyses tested associations when appropriate. RESULTS:Of 100 deliveries (interquartile range, 30-35; median, 33 years old), 58 were C-sections and 42 VDs. Peripartum biologic exposure occurred in 72% (42 of 58) and 57% (24 of 42), respectively. Median time from last dose to delivery was 6 (interquartile range, 4-8) weeks; 21 (32%) received biologics within 72 hours following delivery. Seven infections occurred following C-section among 5 unique CD patients. Peripartum biologic exposure was not associated with infection (4 of 66 [6%] exposed vs 3 of 34 [8.8%] nonexposed; P = .68), nor was disease activity (P = 1.0). Crohn's disease (P = 0.02), internal penetrating phenotype (P < .001), prior IBD surgery (P = .03), and prior postpartum infection (P = .04) were associated with infection. CONCLUSIONS:Peripartum biologic exposure does not impair postpartum wound healing; however, patients with more complicated disease phenotypes require close monitoring.
PMID: 34272560
ISSN: 1536-4844
CID: 4947662

Improving Postpartum Attendance among Women with Gestational Diabetes Using the Medical Home Model of Care

Soffer, Marti D; Rekawek, Patricia; Pan, Stephanie; Overbey, Jessica; Stone, Joanne
OBJECTIVE: Poor attendance at the 6-week postpartum (PP) visit has been well reported. Attendance at this visit is crucial to identify women who have persistent diabetes mellitus (DM) following pregnancies affected by gestational DM (GDM). The medical home model has eliminated barriers to care in various other settings. This study sought to improve PP attendance among women with GDM by jointly scheduling PP visits and the 2-month well infant visits. STUDY DESIGN/METHODS: All patients with a diagnosis of GDM who received care at a New York City-based publicly insured hospital clinic and delivered between October 2017 and June 2019 were eligible. Data were obtained via chart review. The primary outcome was attendance at the PP visit compared with previously published historical controls. Secondary outcomes were rates of PP glucose screening and well infant attendance. RESULTS: = 0.84). CONCLUSION/CONCLUSIONS: This study was unable to improve PP visit attendance among women with GDM by jointly scheduling the 6-week PP visit and the 2-month well-infant visit. Future research could be directed toward a shared space where both women and children can be seen to attempt to increase PP visit attendance and monitoring for women with GDM. KEY POINTS/CONCLUSIONS:· Attendance at the PP visit is poor, and without a visit, women with pregnancies affected by gestational diabetes remain unscreened for PP dysglycemia.. · Jointly scheduling women and their infants to eliminate barriers to care studied by this group, however, were unable to improve attendance.. · Innovative strategies are needed to improve PP attendance among women with pregnancies affected by GDM..
PMID: 33878773
ISSN: 1098-8785
CID: 4847072

COVID-19 Infection and Placental Histopathology in Women Delivering at Term

Patberg, Elizabeth T; Adams, Tracy; Rekawek, Patricia; Vahanian, Sevan A; Akerman, Meredith; Hernandez, Andrea; Rapkiewicz, Amy V; Ragolia, Louis; Sicuranza, Genevieve; Chavez, Martin R; Vintzileos, Anthony M; Khullar, Poonam
BACKGROUND:- There is a paucity of data describing the effects of COVID-19, especially in asymptomatic patients, on placental pathology. Although the pathophysiology of COVID-19 is not completely understood, there is emerging evidence that it causes a severe systemic inflammatory response and results in a hypercoagulable state with widespread microthrombi. We hypothesized that it is plausible that a similar disease process may occur in the fetal-maternal unit. OBJECTIVE:- The aim of this study was to determine whether COVID-19 in term patients admitted to Labor and Delivery, including women without COVID-19 symptomatology, is associated with increased placental injury compared to a cohort of COVID-19 negative controls. STUDY DESIGN/METHODS:- This was a retrospective cohort study performed at NYU Winthrop Hospital between 3/31/2020 and 6/17/2020. During the study period all women admitted to Labor and Delivery were routinely tested for SARS-CoV-2 regardless of symptomatology. The placental histopathological findings of COVID-19 patients (n=77) who delivered a singleton gestation at term were compared to a control group of term patients without COVID-19 (n=56). Controls were excluded if they had obstetric or medical complications including fetal growth restriction, oligohydramnios, hypertension, diabetes, coagulopathy or thrombophilia. Multivariable logistic regression models were performed for variables that were significant in univariable analyses. A subgroup analysis was also performed comparing asymptomatic COVID-19 cases to negative controls. RESULTS:- In univariable analyses, COVID-19 cases were more likely to have evidence of fetal vascular malperfusion, i.e. presence of avascular villi and/or mural fibrin deposition (32.5% (25/77) vs. 3.6% (2/56), p<0.0001) and villitis of unknown etiology (20.8% (16/77) vs. 7.1% (4/56), p=0.030). These findings persisted in a subgroup analysis of asymptomatic COVID-19 cases compared to COVID-19 negative controls. In a multivariable model adjusting for maternal age, race/ethnicity, mode of delivery, preeclampsia, fetal growth restriction and oligohydramnios, the frequency of fetal vascular malperfusion abnormalities remained significantly higher in the COVID-19 group (OR= 12.63, 95% CI [2.40, 66.40]). While the frequency of villitis of unknown etiology was more than double in COVID-19 cases compared to controls, this did not reach statistical significance in a similar multivariable model (OR=2.11, 95% CI [0.50, 8.97]). All neonates of mothers with COVID-19 tested negative for SARS-CoV-2 by PCR. CONCLUSIONS:- Despite the fact that all neonates born to mothers with COVID-19 were negative for SARS-CoV-2 by PCR, we found that COVID-19 in term patients admitted to Labor and Delivery is associated with increased rates of placental histopathologic abnormalities, particularly fetal vascular malperfusion and villitis of unknown etiology. These findings appear to occur even among asymptomatic term patients.
PMCID:7571377
PMID: 33091406
ISSN: 1097-6868
CID: 4642442

The clinical utility of magnetic resonance imaging as an adjunct to ultrasound in the diagnosis of placenta accreta spectrum disorders

Rekawek, Patricia; Liu, Lilly; Pan, Stephanie; Overbey, Jessica; Wagner, Brian
OBJECTIVES/UNASSIGNED:To determine if the use of magnetic resonance imaging (MRI) changes the diagnosis of placenta accreta spectrum (PAS) made on prenatal ultrasound (US) leading to an improvement in clinical outcomes. METHODS/UNASSIGNED:-test and Chi-squared test were performed to compare the clinical outcomes of patients with an upgraded diagnosis by MRI to those whose diagnosis was downgraded or stayed the same. RESULTS/UNASSIGNED: = 0.001]. There were no complications from these procedures. CONCLUSION/UNASSIGNED:The use of MRI incorrectly changed the diagnosis as much as it correctly changed the diagnosis of PAS after US. MRI should not be used routinely as a clinical adjunct to ultrasound in the diagnosis of placenta accreta spectrum.
PMID: 33771092
ISSN: 1476-4954
CID: 4830222

Partner Violence During Pregnancy: The Role of an Oral and Maxillofacial Surgeon

Rekawek, Peter; Kim, Patrick; Rekawek, Patricia; Panchal, Neeraj
PMID: 32931745
ISSN: 1531-5053
CID: 4592922

Ketorolac use for postpartum pain management in women with inflammatory bowel disease (IBD) [Meeting Abstract]

Johnson, Shaelyn; Rekawek, Patricia; Yan, Xiteng; Stoffels, Guillaume; Dubinsky, Marla; Mella, Maria Teresa
ISI:000621547400343
ISSN: 0002-9378
CID: 4821152

Inflammatory bowel disease in pregnancy and prevalence of group B streptococcus colonization [Meeting Abstract]

Johnson, Shaelyn; Pena, Juan; Rekawek, Patricia; Antoine, Ali M.; Dubinsky, Marla; Mella, Maria Teresa
ISI:000621547400183
ISSN: 0002-9378
CID: 4821132

Coronavirus disease 2019 infection and placental histopathology in women delivering at term

Patberg, Elizabeth T.; Adams, Tracy; Rekawek, Patricia; Vahanian, Sevan A.; Akerman, Meredith; Hernandez, Andrea; Rapkiewicz, Amy V.; Ragolia, Louis; Sicuranza, Genevieve; Chavez, Martin R.; Vintzileos, Anthony M.; Khullar, Poonam
ISI:000637866800014
ISSN: 0002-9378
CID: 5016142

Large-for-gestational age diagnosed during second-trimester anatomy ultrasound and association with gestational diabetes and large-for-gestational age at birth

Rekawek, Patricia; Liu, Lilly; Getrajdman, Chloe; Brooks, Casey; Pan, Stephanie; Overbey, Jessica; Wagner, Brian
OBJECTIVES/OBJECTIVE:To determine if large for gestational age (LGA) diagnosed during second trimester ultrasound is associated with the development of gestational diabetes mellitus (GDM) and LGA at birth. METHODS:percentile. Prenatal and delivery records were reviewed and demographic and outcome variables were collected. Multivariable logistic regression models were performed to assess the impact of LGA at second trimester on the development of GDM and LGA at birth. RESULTS:There were 756 LGA and 756 AGA patients included in this study. In patients with LGA diagnosed during second trimester ultrasound, the incidence of GDM was 6% and the incidence of LGA at birth was 14.9%. Among patients with LGA in the second trimester, those who developed GDM or LGA at birth were significantly older, and were more likely to be obese. Moreover, parity was associated with neonatal LGA (P = 0.0003) but not with GDM at birth (P = 0.82). In adjusted analyses, LGA diagnosis during second trimester was significantly associated with GDM (OR 2.54; 95% CI: 1.29, 5.03) and neonatal LGA at birth (OR 6.85, 95% CI 3.60, 13.05; p<0.0001). CONCLUSIONS:LGA diagnosis during second trimester ultrasound is associated with the development of GDM and LGA at birth, independent of women with known risk factors, and could be used to identify these women earlier for intervention. This article is protected by copyright. All rights reserved.
PMID: 31763722
ISSN: 1469-0705
CID: 4237452